Skip to content
Menu

Dyne Therapeutics, Inc. DYN

Full chart Compare
Set alert

Price alert · DYN

All alert types
15.50 USD -0.53 (-3.31%)

Regular-session close

15.50 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

15.41 Day range 16.48
14.00 52-week range 27.31
YTD
-20.76%
1 year
-22.96%

5D -1.64 (-9.37%)

1617ThuFriMonTueWed15.87
Market cap
2.90B
EPS (ttm)
-3.62
Shares out
187.39M
Forward P/E
-4.30
YTD return
-20.76%
1-year return
-22.96%
50-day average
16.61
200-day average
19.28
Enterprise value
2.11B
Price / book
3.12
Volume
2.22M
Avg volume
2.92M
Open
15.91
Previous close
16.03
Day's range
15.41 – 16.48
52-week range
14.00 – 27.31
Beta
1.21
Analysts
Strong Buy
Price target
34.33 (+121.5%)
Earnings date
Mar 1, 2027

Key statistics

Free cash flow
-367.76M
Total cash
1.13B
Total debt
244.28M
Return on equity
-74.56%
Short % of float
16.62%

Fundamental scorecard

4 of 25 checks passed on DYN’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
DYN Revenue — quarterly 0
DYN Net income — quarterly -193.55M
DYN EPS — quarterly -1.06

Earnings

DYN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 1, 2027Dec 30, 2026-1.00———
Nov 5, 2026Sep 30, 2026-0.90728-1.06-0.15-16.83%
Jul 30, 2026Jun 30, 2026-0.74878-1.08-0.33-44.23%
May 11, 2026Mar 31, 2026-0.77229-0.73+0.04+5.48%
Mar 2, 2026Dec 31, 2025-0.74-0.76-0.02-2.70%
Nov 5, 2025Sep 30, 2025-0.81-0.76+0.05+6.17%

Upgrades / downgrades

DYN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 28, 2026OppenheimerdownOutperformPerform
Sep 30, 2026Chardan CapitalmainBuyBuy
Sep 30, 2026HC Wainwright & Co.mainBuyBuy
Sep 29, 2026Piper SandlerreitOverweightOverweight
Sep 9, 2026Morgan StanleymainOverweightOverweight
Sep 9, 2026JP MorgandownNeutralUnderweight

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
dyne-tx.com

News

Your note

Sign in to keep a note on DYN — it syncs with the Stock Master app.

Insider holders

DYN insider holders
InsiderRelationLatest transactionDateShares held
BESKROVNAYA OXANAOfficerSaleMar 10, 2025195,840
COX JOHNChief Executive OfficerSaleNov 12, 2026423,994
FRIEDL-NADERER JOHANNAOfficerSaleNov 12, 2026152,666
KERR DOUGLASOfficerSaleNov 12, 2026167,960
KERSTEN DIRKDirectorSaleJul 26, 20260
LUBNER DAVID CHARLESDirectorStock GiftApr 23, 20260

Institution ownership

DYN institution ownership
Holder% heldSharesValueReported
T. Rowe Price Investment Management, Inc.18.30%34,273,516531.24MSep 29, 2026
Blackrock Inc.7.73%14,471,562224.31MSep 29, 2026
Janus Henderson Group Ltd.6.43%12,042,371186.66MSep 29, 2026
FMR, LLC5.95%11,146,369172.77MSep 29, 2026
Wellington Management Group, LLP5.65%10,579,924163.99MSep 29, 2026
State Street Corporation4.36%8,158,310126.45MSep 29, 2026

Fund ownership

DYN fund ownership
Holder% heldSharesValueReported
T. Rowe Price Small-Cap Stock Fund, Inc.3.74%7,004,602108.57MJun 29, 2026
T. Rowe Price Small-Cap Value Fund, Inc.2.46%4,602,62971.34MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.39%4,471,72769.31MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.32%4,349,70467.42MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.13%3,986,20861.79MSep 29, 2026
T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd.2.03%3,809,72159.05MJun 29, 2026